VERO Biotech’s GENOSYL® Delivery System recognized as a “Technological Breakthrough” at Premier, Inc.’s Annual Supplier Innovation Celebration

Vero will be honored as an “Innovative Supplier” at Premier’s Annual Breakthroughs Conference and Exhibition (BREAKTHROUGHS 2023) taking place June 20-22 in Nashville, TN

June 14, 2023 – Atlanta, GA –  VERO Biotech Inc., a commercial-stage healthcare business dedicated to neonatal intensive care and the acute care hospital community, today announced that it will be honored during Premier, Inc.’s annual supplier Innovation Celebration at the  2023 Breakthroughs Conference and Exhibition.

VERO Biotech’s GENOSYL® Delivery System (DS) will be recognized as a “Technological Breakthrough.”  VERO Biotech ’s GENOSYL® DS – the first tankless nitric oxide delivery system approved by the FDA – will be one of only seven innovations honored during Premier’s supplier Innovation Celebration, which recognizes groundbreaking healthcare technologies that have been launched throughout the year and the ways these products are helping to improve the health of communities. 

“We are honored to receive this recognition from Premier. We are deeply committed to continued innovation so that we may better serve patients, respiratory therapists, and healthcare providers.” said Brent V. Furse, CEO and President,  VERO Biotech

Premier is a leading healthcare improvement company, uniting an alliance of approximately 4,400 U.S. hospitals and 250,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, consulting and other services, Premier enables better care and outcomes at a lower cost.

GENOSYL DS is the first tankless inhaled nitric oxide delivery system approved by the U.S. Food and Drug Administration (FDA). Inhaled Nitric Oxide dilates pulmonary blood vessels and may be used to improve oxygenation in neonates with hypoxic respiratory failure and pulmonary hypertension. Unlike tank-based systems, GENOSYL DS generates and delivers iNO at the bedside using a small disposable cassette. This eliminates the need for hospitals to manage large, cumbersome tanks, helps to simplify clinical workflow, and streamlines patient care. 

About GENOSYL®

Indication

GENOSYL (nitric oxide) gas, for inhalation, is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents. 

Important Safety Information

·      GENOSYLis  contraindicated  in the treatment of neonates dependent on right-to-left shunting of blood.

·      Abrupt discontinuation of GENOSYL (nitric oxide) gas, for inhalation may lead to worsening oxygenation and increasing pulmonary artery pressure.

·      Methemoglobin levels in the blood increase with the dose of nitric oxide; following discontinuation or reduction of nitric oxide, methemoglobin levels return to baseline over a period of hours. 

·      Methemoglobin, NO2, and PaO2 should be monitored during nitric oxide administration.

·      In patients with pre-existing left ventricular dysfunction, GENOSYL may increase pulmonary capillary wedge pressure leading to pulmonary edema.

·      The most common adverse reaction is hypotension.

·      Nitric oxide donor compounds may have an additive effect with GENOSYL on the risk of developing methemoglobinemia.

·      GENOSYL must be administered using a calibrated GENOSYL Delivery System.  Only validated ventilator systems or nasal cannulas should be used in conjunction with GENOSYL.

About GENOSYL ®  DS

GENOSYL DS is a tankless system engineered with redundant backup features that delivers a constant concentration of inhaled nitric oxide gas to patients with an easy-to-use interface and portability features. This proprietary delivery system eliminates the need for large nitric oxide tanks and the associated logistical burden.  GENOSYL DS recently received FDA approval for its innovative dual-cassette design and secondary adaptive sensor technology to further optimize patient care.

About VERO Biotech 

VERO Biotech Inc. is a privately held company headquartered in Atlanta, Georgia focused on saving lives, alleviating suffering, and improving health economics in the neonatal intensive care and the acute care hospital communities.

Forward Looking Statements

This press release and any statements of representatives of VERO Biotech Inc. related thereto that are not historical in nature contain, or may contain, among other things, certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, without limitation, statements with respect to VERO Biotech’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “seeks,” “intends,” “plans,” “potential” or similar expressions, including statements with respect to the potential benefits, advantages or market opportunity of the products.  These statements are based upon the current beliefs and expectations of VERO Biotech’s management and are subject to significant risks and uncertainties.  Actual results may differ significantly from those set forth in the forward-looking statements.  These forward-looking statements involve certain risks and uncertainties that are subject to change based on various risk factors (many of which are beyond the control of VERO Biotech). 

For information, please visit  www.vero-biotech.com  or contact Ziad Mohamed at  contactus@vero-biotech.com .

By Sheran Brown June 24, 2025
The Life Sciences Workforce Collaborative (LSWC) has released the 2025 Life Sciences Workforce Trends Report—offering one of the most comprehensive pictures to date of the hiring, training, and talent dynamics shaping the future of the industry. Developed in partnership with TEConomy Partners, LLC , and supported by InnovATEBIO , this seventh edition of the biennial report is based on a rich set of national data: ● Survey responses from over 500 life sciences companies across 30 states and Puerto Rico ● Executive interviews with more than 200 industry leaders ● Analysis of 2.9 million unique job postings from the past four years Together, these inputs paint a nuanced picture of a sector in transition—where innovation is thriving, but economic pressures and rapid technological change are forcing organizations to rethink their workforce strategies. Slower Growth, But Not a Slowdown in Strategy The report finds that after several years of rapid post-pandemic hiring, the U.S. life sciences industry experienced a modest employment contraction of 0.3% in 2024. Hiring has become more strategic, and companies are shifting focus from volume to value—investing in automation, workforce upskilling, and future-forward technologies. Despite the hiring slowdown, long-term growth indicators are strong: more than $200 billion in U.S. life sciences manufacturing and R&D investments have been announced by major companies including Johnson & Johnson, Eli Lilly, Merck, Regeneron, and others. These expansions point to sustained demand for a skilled, resilient, and adaptable workforce. AI, Automation, and the Rise of Hybrid Talent One of the clearest trends in the report is the growing integration of AI, machine learning, and industrial automation across R&D, regulatory, and manufacturing operations. Larger companies are leading adoption, but small and mid-sized firms are quickly following. As these technologies become embedded in daily workflows, employers are seeking “bilingual” workers—those with both technical life sciences expertise and digital fluency. From AI-powered regulatory documentation to predictive maintenance in biomanufacturing, tomorrow’s workforce must be prepared to operate at the intersection of science and software. --- Upskilling, Not Just Hiring With lower turnover and cautious new hiring, many life sciences companies are turning inward—investing more heavily in their existing workforce. Employers report increasing reliance on internal training, microcredentialing, and competency-based assessments, particularly for technical production roles, quality assurance, and regulatory functions. Performance-based credentialing programs, like those offered by the Bioscience Core Skills Institute (BCSI), are helping bridge gaps between traditional education and job-readiness—especially for entry-level and mid-career talent. STEM Engagement Surging Nationwide The report also highlights a remarkable rise in employer involvement in STEM education. Compared to two years ago, more than twice as many companies report engaging with K–12 students through classroom visits, mentorship programs, science fairs, and summer camps. At the postsecondary level, internships, co-op programs, and apprenticeships are helping to build direct pathways into the workforce. Nearly 80% of companies surveyed are actively offering internships to students from four-year institutions, and nearly two-thirds to community college students. This surge in engagement reflects a broader industry focus on ensuring a future-ready talent pipeline—starting early and growing local. Why This Report Matters For employers, educators, and policymakers, the 2025 Life Sciences Workforce Trends Report is more than a snapshot—it’s a strategic tool. With workforce challenges affecting everything from drug development to supply chain resilience, coordinated, data-informed action is more urgent than ever. “This report illustrates a new era in workforce dynamics—where slower overall growth is paired with opportunity in key areas, growing emphasis on upskilling, and a shift toward technology-integrated roles,” said Liisa Bozinovic, Executive Director of Oregon Bio and Chair of LSWC. “At BIO, we are proud to support these efforts and to champion policies that strengthen our industry’s talent pipeline, from the classroom to the lab and beyond,” added John Crowley, President & CEO of the Biotechnology Innovation Organization (BIO). “As noted by the National Security Commission on Emerging Biotechnology, keeping pace with the rapidly evolving skills and talent needs of the biotechnology sector is essential to U.S. leadership in this industry,” said Linnea Fletcher, Principal Investigator at InnovATEBIO. “Our national network of advanced technical education programs is working nimbly to build the next generation of biotech talent—one that is diverse, industry-aligned, and ready to power the biotechnology revolution.” --- Access the Full Report The full 2025 Life Sciences Workforce Trends Report is now available to download: https://www.lifesciencesworkforce.org/national-workforce-trends To learn more about the Life Sciences Workforce Collaborative and how your organization can engage, visit: www.LifeSciencesWorkforce.org Follow LSWC on social media for highlights and updates: 🔹 Twitter/X: X: @LifeSciWork 🔹 LinkedIn: Life Sciences Workforce Collaborative 🔹 Instagram: @lifesciworkforce 🔹 YouTube: @lifesciworkforce
By Sheran Brown June 17, 2025
This week marks an important milestone for workforce development in the U.S. life sciences sector: the official launch of the Life Sciences Workforce Collaborative (LSWC) . Formerly known as the Coalition of State Bioscience Institutes (CSBI) , LSWC premiered at the 2025 BIO International Convention as a new national nonprofit—building on over a decade of state and regional leadership to expand industry-aligned solutions for talent development. As the life sciences industry confronts evolving technologies, shifting economic headwinds, and persistent workforce challenges - including specialized talent needs, unmet demand for skilled biomanufacturers, positioning for future growth —LSWC offers a unified platform to scale solutions, support workforce readiness, and strengthen public-private partnerships across the country. Just out of the gate, the new organization is pleased to announce a major insight-driven release later this month: the upcoming 2025 National Life Sciences Workforce Trends Report , produced in partnership with TEConomy Partners and the NSF-funded InnovATEBIO National Biotech Education Center . Comprised of data from over 700 life science companies and 2.9 million job postings, the report will go live on June 24, 2025. Why This Matters The newly launched LSWC builds on more than a decade of trusted collaboration among 50+ state, regional and national life science organizations and workforce partners. Its mission: to align, advise, and accelerate talent development efforts across the entire life sciences talent pipeline—from middle school to mid-career--to build a competitive life sciences workforce. Next week, the LSWC will launch the 2025 National Workforce Trends Report, the organization’s flagship effort. Now in its seventh edition, this biennial report draws on: Responses from over 500 companies across 30 states and Puerto Rico Interviews with over 200 life science executives Analysis of 2.9 million unique job postings across the U.S. from the last four years The report is the definitive source for understanding the real-world trends shaping hiring, upskilling, and STEM education engagement across the life sciences ecosystem. More to come next week. What Comes Next In the weeks ahead, we’ll be working with our partners to roll out media toolkits, schedule events, and activate coordinated campaigns to bring visibility to both the LSWC launch and the report. We are deeply grateful to our investor-level supporters—AZBio/AZ Advances, BioNJ, BioUtah, California Life Sciences, Georgia Life Sciences/Institute, Colorado Bioscience Association/Institute, MichBio, NewYorkBIO/Institute, Ohio Life Sciences, Oregon Bioscience Association, SCbio, and Southern California Biomedical Council (SoCalBio)—LSWC partners and connectors, and to every organization that has shaped this initiative from the ground up. Together, we are building a stronger, competitive, and future-ready workforce—one that ensures the U.S. remains the global leader in biotechnology, biomanufacturing, and life sciences innovation. Stay tuned and learn how you can partner with us to advance the life sciences workforce. Learn more at: www.LifeSciencesWorkforce.org For media inquiries: connect@lifesciencesworkforce.org
By Sheran Brown June 16, 2025
GLS has been named a new Spoke Member of the ARPA‑H Customer Experience Hub—ARPA‑H’s patient‑centric network dedicated to embedding real-world user insights and representation into health innovation. As part of the nationwide ARPANET‑H hub‑and‑spoke initiative (with hubs in Dallas, Boston, and D.C.), Georgia Life Sciences will help prioritize inclusive design, usability testing, and equitable trial participation in next-gen therapies.
MORE POSTS